Ongoing phase 3 trials of BTK-BCL2 inhibitor combinations in treatment-naive CLL
| Study name . | ClinicalTrials.gov Identifier . | Regimen . | Eligibility . |
|---|---|---|---|
| CLL16 (German CLL Study Group) | NCT05197192 | Acalabrutinib + obinutuzumab + venetoclax vs obinutuzumab + venetoclax | High risk with either del(17p), TP53 mutation, or complex karyotype |
| A041702 (Alliance) | NCT03737981 | Ibrutinib + obinutuzumab + venetoclax vs ibrutinib + obinutuzumab | ≥65 years old |
| EA9161 (ECOG-ACRIN) | NCT03701282 | Ibrutinib + obinutuzumab + venetoclax vs ibrutinib + obinutuzumab | < 70 years old without del(17p) |
| MAJIC | NCT05057494 | Acalabrutinib + venetoclax vs obinutuzumab + venetoclax | ≥18 years old No stipulation prognostic markers |
| CLL-17 (German CLL Study Group) | NCT04608318 | Continuous ibrutinib vs obinutuzumab + venetoclax vs fixed-duration ibrutinib + venetoclax | ≥18 years old No stipulation prognostic markers |
| Study name . | ClinicalTrials.gov Identifier . | Regimen . | Eligibility . |
|---|---|---|---|
| CLL16 (German CLL Study Group) | NCT05197192 | Acalabrutinib + obinutuzumab + venetoclax vs obinutuzumab + venetoclax | High risk with either del(17p), TP53 mutation, or complex karyotype |
| A041702 (Alliance) | NCT03737981 | Ibrutinib + obinutuzumab + venetoclax vs ibrutinib + obinutuzumab | ≥65 years old |
| EA9161 (ECOG-ACRIN) | NCT03701282 | Ibrutinib + obinutuzumab + venetoclax vs ibrutinib + obinutuzumab | < 70 years old without del(17p) |
| MAJIC | NCT05057494 | Acalabrutinib + venetoclax vs obinutuzumab + venetoclax | ≥18 years old No stipulation prognostic markers |
| CLL-17 (German CLL Study Group) | NCT04608318 | Continuous ibrutinib vs obinutuzumab + venetoclax vs fixed-duration ibrutinib + venetoclax | ≥18 years old No stipulation prognostic markers |